Moderna flu vaccine shows superior efficacy in phase 3 study

May 6, 2026 5:16 PM

Moderna Inc. (NASDAQ: MRNA) announced that the New England Journal of Medicine published results from its Phase 3 clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found